Nothing Special   »   [go: up one dir, main page]

TR200001909T2 - Matris metaloprotez inhibitörleri. - Google Patents

Matris metaloprotez inhibitörleri.

Info

Publication number
TR200001909T2
TR200001909T2 TR2000/01909T TR200001909T TR200001909T2 TR 200001909 T2 TR200001909 T2 TR 200001909T2 TR 2000/01909 T TR2000/01909 T TR 2000/01909T TR 200001909 T TR200001909 T TR 200001909T TR 200001909 T2 TR200001909 T2 TR 200001909T2
Authority
TR
Turkey
Prior art keywords
inhibitors
matrix
metalloprosthesis
substituents
compounds
Prior art date
Application number
TR2000/01909T
Other languages
English (en)
Inventor
Jonathan Fray Michael
Peter Dickinson Roger
Neil Dack Kevin
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9800510.1A external-priority patent/GB9800510D0/en
Priority claimed from GBGB9811843.3A external-priority patent/GB9811843D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of TR200001909T2 publication Critical patent/TR200001909T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/18—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formül (I)'in bilesimleri ya da onun farmasötik olarak uygun tuzlari ya da her iki türde çözeltileri, burada ikameler burada tanimlanan degerlere sahiptir, matris metalloproteaz önleyicileri olarak yararlidirlar.
TR2000/01909T 1998-01-09 1998-12-23 Matris metaloprotez inhibitörleri. TR200001909T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9800510.1A GB9800510D0 (en) 1998-01-09 1998-01-09 Therapeutic agents
GBGB9811843.3A GB9811843D0 (en) 1998-06-02 1998-06-02 Therapeutic agents

Publications (1)

Publication Number Publication Date
TR200001909T2 true TR200001909T2 (tr) 2000-12-21

Family

ID=26312925

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/01909T TR200001909T2 (tr) 1998-01-09 1998-12-23 Matris metaloprotez inhibitörleri.

Country Status (37)

Country Link
US (1) US6350907B1 (tr)
EP (1) EP1047665B1 (tr)
JP (1) JP3621884B2 (tr)
KR (1) KR100385662B1 (tr)
CN (1) CN1284942A (tr)
AP (1) AP1059A (tr)
AR (1) AR014270A1 (tr)
AT (1) ATE252547T1 (tr)
AU (1) AU736511B2 (tr)
BG (1) BG104575A (tr)
BR (1) BR9813719A (tr)
CA (1) CA2317604C (tr)
CO (1) CO4990971A1 (tr)
CZ (1) CZ20002459A3 (tr)
DE (1) DE69819206T2 (tr)
DK (1) DK1047665T3 (tr)
DZ (1) DZ2701A1 (tr)
EA (1) EA002971B1 (tr)
ES (1) ES2209244T3 (tr)
HN (1) HN1998000199A (tr)
HR (1) HRP20000460A2 (tr)
HU (1) HUP0101300A3 (tr)
IL (1) IL136889A0 (tr)
IS (1) IS5531A (tr)
MA (1) MA26594A1 (tr)
NO (1) NO20003506D0 (tr)
NZ (1) NZ504683A (tr)
OA (1) OA11435A (tr)
PA (1) PA8466101A1 (tr)
PE (1) PE20000176A1 (tr)
PL (1) PL342763A1 (tr)
PT (1) PT1047665E (tr)
SI (1) SI1047665T1 (tr)
SK (1) SK10112000A3 (tr)
TN (1) TNSN99002A1 (tr)
TR (1) TR200001909T2 (tr)
WO (1) WO1999035124A1 (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356919A1 (en) * 1998-12-31 2000-07-13 Michael J. Janusz Selective inhibitors of mmp-12
US6352976B1 (en) 1998-12-31 2002-03-05 Aventis Pharmaceuticals Inc. Selective inhibitors of MMP-12
JP2001055327A (ja) * 1999-06-11 2001-02-27 Fuji Chemical Industries Ltd 新規なヒドロキサム酸誘導体を含む医薬
GB0025310D0 (en) * 2000-10-16 2000-11-29 Pfizer Ltd Process
US6452041B1 (en) 2000-10-16 2002-09-17 Pfizer Inc. Olefination process to itaconate and succinate derivatives
BR0207307A (pt) * 2001-02-16 2004-08-17 Allelix Neuroscience Inc Inibidores de glyt-1
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
PA8578101A1 (es) * 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
US20040138103A1 (en) * 2002-11-07 2004-07-15 Procyte Corporation Compositions containing peptide copper complexes and metalloproteinase inhibitors and methods related thereto
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
AU2004266896B2 (en) * 2003-08-23 2010-08-19 Merck Serono Sa Derivatives of hydroxamic acid as metalloproteinase inhibitors
ES2545688T3 (es) * 2006-09-29 2015-09-15 F. Hoffmann-La Roche Ag Método de evaluación del riesgo de progresión de enfermedad de pacientes con artritis reumatoide
CN104788333B (zh) * 2015-03-19 2017-03-22 中国医科大学 2‑取代‑9,10‑蒽醌类化合物、制备方法及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
CA2149640A1 (en) 1992-11-25 1994-06-09 Kevin T. Chapman Carboxy-peptidyl derivatives as antidegenerative active agents
ATE182137T1 (de) 1993-04-27 1999-07-15 Celltech Therapeutics Ltd Peptidylderivate als inhibitoren von metalloproteinase
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9320660D0 (en) 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
BR9506535A (pt) 1994-01-20 1997-09-16 British Biotech Pharm Inibidores de metaloproteinases
ES2139183T3 (es) 1994-01-22 2000-02-01 British Biotech Pharm Inhibidores de las metaloproteinasas.
US6028110A (en) 1994-05-28 2000-02-22 British Biotech Pharmaceuticals Ltd. Succinyl hydroxamic acid, N-formyl-N-hydroxy amino carboxylic acid and succinic acid amide derivatives as metalloprotease inhibitors
US5461746A (en) * 1995-01-17 1995-10-31 Tdw Delaware, Inc. Magnetic cleaning pig
GB9507799D0 (en) * 1995-04-18 1995-05-31 British Biotech Pharm Metalloproteinase inhibitors
US5691381A (en) 1995-04-18 1997-11-25 The Dupont Merck Pharmaceutical Company Hydroxamic and carbocyclic acids as metalloprotease inhibitors
ES2184861T3 (es) 1995-05-10 2003-04-16 Darwin Discovery Ltd Compuestos peptidicos inhibidores de la liberacion de la metaloproteinasa y del tnf y su utilizacion terapeutica.
JPH11504934A (ja) 1995-05-10 1999-05-11 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチジル化合物およびその治療的使用
US5917090A (en) * 1995-06-30 1999-06-29 British Biotech Pharmaceuticals Ltd. Matrix metalloproteinase inhibitors
GB9513331D0 (en) 1995-06-30 1995-09-06 British Biotech Pharm Matrix metalloproteinase inhibitors
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors

Also Published As

Publication number Publication date
AU736511B2 (en) 2001-07-26
EP1047665A1 (en) 2000-11-02
HUP0101300A2 (hu) 2001-08-28
NZ504683A (en) 2002-06-28
JP3621884B2 (ja) 2005-02-16
DE69819206T2 (de) 2004-04-15
CZ20002459A3 (cs) 2001-12-12
NO20003506L (no) 2000-07-07
EP1047665B1 (en) 2003-10-22
SI1047665T1 (en) 2004-02-29
ATE252547T1 (de) 2003-11-15
NO20003506D0 (no) 2000-07-07
KR20010033990A (ko) 2001-04-25
AR014270A1 (es) 2001-02-07
KR100385662B1 (ko) 2003-05-28
TNSN99002A1 (fr) 2005-11-10
HRP20000460A2 (en) 2001-06-30
DK1047665T3 (da) 2004-02-02
CA2317604C (en) 2004-12-21
PL342763A1 (en) 2001-07-02
DE69819206D1 (de) 2003-11-27
IL136889A0 (en) 2001-06-14
AP1059A (en) 2002-04-22
PE20000176A1 (es) 2000-03-10
CN1284942A (zh) 2001-02-21
JP2002500215A (ja) 2002-01-08
WO1999035124A1 (en) 1999-07-15
CO4990971A1 (es) 2000-12-26
AU2277699A (en) 1999-07-26
PA8466101A1 (es) 2000-05-24
EA002971B1 (ru) 2002-12-26
DZ2701A1 (fr) 2003-09-01
IS5531A (is) 2000-06-13
BG104575A (en) 2001-02-28
HN1998000199A (es) 2000-11-03
BR9813719A (pt) 2000-10-17
US6350907B1 (en) 2002-02-26
OA11435A (en) 2004-04-28
HUP0101300A3 (en) 2002-11-28
AP9901436A0 (en) 1999-03-31
EA200000628A1 (ru) 2001-02-26
PT1047665E (pt) 2004-01-30
SK10112000A3 (sk) 2002-02-05
CA2317604A1 (en) 1999-07-15
MA26594A1 (fr) 2004-12-20
ES2209244T3 (es) 2004-06-16

Similar Documents

Publication Publication Date Title
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK0931788T3 (da) Metalloproteasehæmmere
NL350075I2 (tr)
RS49688B (sr) Novi derivat 3-aril-2- hidroksipropionske kiseline (i)
TR200100605T2 (tr) Arilpiperazinler ve bunların metaloproteinaz inhibe edici maddeler (MMP) olarak kullanımı
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
PT1413582E (pt) Pirrolobenzodiazepinas dimericas
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
SE9802208D0 (sv) Novel compounds
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
TR200001452T2 (tr) Bifenilamidin türevleri.
NO20015892D0 (no) Inhibitorer av metallproteinaser
DE60117594D1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
ATE320422T1 (de) Metalloproteinase inhibitoren
TR200100133T2 (tr) FKBP İnhibitörleri
DE60005517D1 (de) Kaliumkanal-blockierende mittel
RS50033B (sr) Derivati etansulfonil-piperidina
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
TR200001122T2 (tr) Farmasötikler olarak bifenil türevleri.
ATE248163T1 (de) Neuartige, pharmazeutisch aktive verbindung
TR200100222T2 (tr) Ürokinaz önleyicileri olarak izokinolinler
TR199902117T2 (tr) (E)-4,6- Dikloro-3-(2-okso-1-fenilpirolidin-3-iliden metil)-1H-Indol-2-karboksilik asidin kristalimsi hidratlanmis sodyum tuzu.
ES2185708T3 (es) Inhibicion de la biosintesis de leucotrienos con derivados de urea.
AP2001002047A0 (en) Isoquinoliness as urokinase inhibitors.
ATE261962T1 (de) Benzonaphtyridin-1,8 derivate